Key Points
- Director Kristine Ball sold 18,000 shares for about $1.89 million, cutting her stake by 50%; the sale was made under a pre-arranged Rule 10b5-1 plan.
- Oruka reported a quarterly loss of $0.63 per share, missing analysts’ estimate of a $0.60 loss.
- Analysts remain broadly positive: nine rate ORKA Buy and one Sell, with a “Moderate Buy” consensus and an average price target of $141.80.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) SVP Arjun Agarwal sold 10,000 shares of the business's stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $104.97, for a total transaction of $1,049,700.00. Following the completion of the transaction, the senior vice president owned 14,219 shares in the company, valued at $1,492,568.43. The trade was a 41.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Arjun Agarwal also recently made the following trade(s):
- On Monday, October 12th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.60, for a total transaction of $805,919.40.
- On Monday, September 21st, Arjun Agarwal sold 533 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.75, for a total transaction of $51,034.75.
- On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total transaction of $53,597.60.
- On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.23, for a total transaction of $872,403.57.
Oruka Therapeutics Price Performance
Shares of ORKA stock traded up $0.36 during trading on Friday, hitting $105.35. 679,678 shares of the stock traded hands, compared to its average volume of 1,033,539. Oruka Therapeutics, Inc. has a 52-week low of $25.23 and a 52-week high of $115.51. The firm has a market capitalization of $7.14 billion, a P/E ratio of -49.93 and a beta of -0.34. The firm's fifty day moving average price is $89.68 and its 200-day moving average price is $72.36.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). As a group, equities research analysts expect that Oruka Therapeutics, Inc. will post -2.52 earnings per share for the current year.
Wall Street Analysts Forecast Growth
ORKA has been the topic of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Weiss Ratings reissued a "sell (d-)" rating on shares of Oruka Therapeutics in a research report on Tuesday, October 13th. Wall Street Zen downgraded Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. Wedbush restated an "outperform" rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, October 27th. Finally, Guggenheim restated a "buy" rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a report on Monday, October 26th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $141.80.
Check Out Our Latest Analysis on ORKA
Key Oruka Therapeutics News
Here's some of the latest news about ORKA:
- Positive Sentiment: BTIG Research and UBS each assigned Oruka a “Buy” rating, providing a positive analyst view. BTIG Research Buy rating UBS Buy rating
- Negative Sentiment: HC Wainwright cut its estimates for every quarter of 2027 and for full-year 2026 and 2027, while keeping its Buy rating. It now expects losses of $2.69 per share in FY2026 and $3.22 in FY2027, versus prior estimates of $2.54 and $2.82, respectively. The deeper projected losses may dampen sentiment.
- Negative Sentiment: Director Kristine M. Ball sold 18,000 shares—half her position—and SVP Arjun Agarwal sold 10,000 shares, reducing his holdings by 41.29%. Both sales were made under pre-arranged Rule 10b5-1 plans, which may lessen their significance as a signal about near-term prospects. Director Form 4 filing SVP Form 4 filing
Hedge Funds Weigh In On Oruka Therapeutics
Several large investors have recently made changes to their positions in ORKA. Nykredit A S purchased a new position in shares of Oruka Therapeutics during the 2nd quarter worth approximately $29,000. GAMMA Investing LLC increased its holdings in Oruka Therapeutics by 201.6% in the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company's stock valued at $31,000 after purchasing an additional 250 shares during the last quarter. Orion Capital Management LLC acquired a new stake in Oruka Therapeutics in the 2nd quarter valued at approximately $91,000. Sterling Capital Management LLC raised its position in Oruka Therapeutics by 839.0% in the third quarter. Sterling Capital Management LLC now owns 1,662 shares of the company's stock valued at $138,000 after purchasing an additional 1,485 shares during the period. Finally, Royal Bank of Canada raised its position in Oruka Therapeutics by 178.5% in the first quarter. Royal Bank of Canada now owns 3,172 shares of the company's stock valued at $155,000 after purchasing an additional 2,033 shares during the period. 56.44% of the stock is currently owned by institutional investors and hedge funds.
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company's pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
